Complete your stack
Tirzepatide
$109.99
Tirzepatide is the once-weekly dual GIP/GLP-1 agonist behind some of the largest metabolic effects in Phase 3 research — now available as premium Tirzepatide Canada reference material, sourced to Helixx’s exacting Canadian peptides standard. For laboratory and educational use only.
Description
Tirzepatide is the dual-incretin peptide that rewrote what a single molecule can do. This once-weekly GIP and GLP-1 receptor agonist produced some of the largest, most consistent metabolic effects ever recorded in Phase 3 trials, and Helixx now makes premium Tirzepatide Canada researchers can rely on, sourced to the same exacting standard as our full line of Canadian peptides.1
What Is Tirzepatide?
Tirzepatide is a synthetic 39-amino-acid peptide engineered as a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. It carries a fatty-diacid acyl chain that binds circulating albumin, extending its half-life enough to support once-weekly dosing in the study protocols where it has been characterized. Among the metabolic peptides Canada researchers are investigating, tirzepatide stands out for combining two incretin pathways in one structure, a design that sets it apart from single-pathway GLP-1 agonists. It is offered here strictly as a reference material for laboratory and educational use only, and is not for human consumption.
How Tirzepatide Works
Tirzepatide behaves as an “imbalanced,” biased dual agonist. Pharmacology work shows it binds the GIP receptor with affinity comparable to native GIP, while binding the GLP-1 receptor roughly five-fold more weakly than native GLP-1; at the GLP-1 receptor it is biased toward cAMP generation over beta-arrestin recruitment, with reduced receptor internalization, and this signaling profile is thought to underlie its enhancement of insulin secretion.1 By activating both incretin receptors at once, the peptide has been observed to enhance glucose-dependent insulin secretion, suppress glucagon, improve insulin sensitivity, and slow gastric emptying while promoting satiety. Together, these actions lower HbA1c and drive substantial, dose-dependent reductions in body weight in the models where it has been studied.
What the Research Shows
- Mechanistic pharmacology. Receptor-binding and signaling studies established tirzepatide as a biased, imbalanced dual GIP/GLP-1 agonist, clarifying how its distinct signaling translates into potentiated insulin secretion.1
- Head-to-head glycemic control (SURPASS-2). In a Phase 3 randomized trial in type 2 diabetes, tirzepatide (5/10/15 mg) was non-inferior and superior to semaglutide 1 mg for HbA1c reduction and produced greater weight loss; gastrointestinal events (nausea, diarrhea, vomiting) were the most common and were mild-to-moderate.2
- Body-weight outcomes (SURMOUNT-1). Over 72 weeks in adults with obesity or overweight, tirzepatide produced substantial, sustained, dose-dependent body-weight reductions (mean approximately 15–21% across 5–15 mg doses versus placebo), with mostly mild-to-moderate gastrointestinal adverse events.3
Researchers comparing incretin candidates often bench tirzepatide alongside the triple-agonist Retatrutide and the single-pathway GLP-1 agonist Ozempic (Semaglutide), while those building broader metabolic and recovery protocols may pair it with AOD9604 or 5-Amino-1MQ.
Chemical Properties
| Research Name | Tirzepatide |
| CAS Number | 2023788-19-2 |
| Molecular Formula | C225H348N48O68 |
| Molecular Weight | 4813.53 g/mol |
| Classification | Dual GIP and GLP-1 receptor agonist (synthetic 39-amino-acid peptide) |
Research Protocols & Handling
This material is supplied exclusively for in-vitro laboratory research and educational purposes. It is not a drug, supplement, or food, and it is not intended for human or veterinary use, diagnosis, treatment, or consumption. Tirzepatide is typically provided as a lyophilized powder, and standard peptide handling applies. Store the sealed vial refrigerated and protected from light, and keep long-term stock frozen. For research reconstitution, bacteriostatic or sterile water is generally used, after which the solution should be kept refrigerated and used within the working window established by the investigator’s own stability data. Avoid repeated freeze-thaw cycles, vigorous shaking, and prolonged exposure to light or heat, all of which can degrade peptide integrity. Handling should be performed only by qualified personnel using appropriate laboratory practices.
Potential Side Effects & Safety
Although this product is not for human use, tirzepatide’s pharmacological effects are well documented in the trial literature, and researchers should understand the full profile:
- Gastrointestinal effects. Nausea is very common and dose-dependent; diarrhea, vomiting, constipation, decreased appetite, dyspepsia, and abdominal pain are also frequently reported. Across Phase 3 trials these events were the most common and were generally mild-to-moderate.23
- Hypoglycemia. Low blood glucose has been observed mainly when the agent is combined with insulin or sulfonylureas.
- Dehydration and kidney effects. Fluid loss secondary to gastrointestinal effects can occur, with rare reports of acute kidney injury.
- Pancreatic and biliary risk. Acute pancreatitis is uncommon but is a recognized class-associated risk; gallbladder and biliary disease, including cholelithiasis, is also class-associated.
- Cardiovascular and general. Increased heart rate, fatigue, and injection-site reactions have been documented.
- Hypersensitivity. Allergic and hypersensitivity reactions have been reported.
- Boxed-warning class risk. Thyroid C-cell tumors (medullary thyroid carcinoma) were observed in rodents with this drug class; the relevance of this finding to humans is unestablished.
Not approved for human consumption in Canada or elsewhere; research and educational use only.
Frequently Asked Questions
Is Tirzepatide legal in Canada?
Tirzepatide is offered by Helixx as a research chemical for laboratory and educational use only. It is not approved or sold as a drug, supplement, or food for human consumption in Canada, and purchasers are responsible for complying with all applicable federal, provincial, and institutional regulations governing the acquisition and use of research materials.
How does Tirzepatide differ from semaglutide?
Semaglutide is a single-pathway GLP-1 receptor agonist, whereas tirzepatide is a dual GIP and GLP-1 receptor agonist. In the SURPASS-2 head-to-head trial, tirzepatide was superior to semaglutide 1 mg for HbA1c reduction and produced greater weight loss.2 You can compare our Ozempic (Semaglutide) listing for the single-agonist reference.
What makes it a “dual agonist”?
Tirzepatide activates two incretin receptors, GIP and GLP-1, from a single peptide structure. Pharmacology studies show it is an imbalanced, biased agonist that binds GIP with native-like affinity while binding GLP-1 more weakly and signaling with a bias toward cAMP generation.1 Researchers exploring even broader incretin coverage sometimes compare it to the triple agonist Retatrutide.
How should Tirzepatide be stored for research?
Keep the lyophilized vial refrigerated and protected from light for short-term storage, and frozen for long-term storage. Once reconstituted with sterile or bacteriostatic water for research, keep the solution refrigerated, avoid repeated freeze-thaw cycles, and use it within the stability window established by your own laboratory data.
References
Peer-reviewed and authoritative sources cited above. Helixx supplies research materials for laboratory and educational use only; citations are provided for independent verification, not as medical guidance.
- Willard FS, Douros JD, Gabe MB, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020;5(17):e140532. PMID: 32730231.
- Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med. 2021;385(6):503-515. PMID: 34170647.
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. PMID: 35658024.
Complete Your Stack
Frequently bought together, add all and unlock VIP pricing.
